These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine]. Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398 [TBL] [Abstract][Full Text] [Related]
45. [Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine]. Pisón Garcés FJ; Galbe Sánchez-Ventura J; Arcauz Eguren P; Aguirre y Dabán C; Mengual Gil J; Larrad Mur L Aten Primaria; 1995 Mar; 15(4):235-7. PubMed ID: 7703334 [TBL] [Abstract][Full Text] [Related]
46. Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR. Mitchell LA; Tingle AJ; Décarie D; Lajeunesse C Can J Public Health; 1998; 89(5):325-8. PubMed ID: 9813922 [TBL] [Abstract][Full Text] [Related]
47. Immunity against measles and rubella in Massachusetts schoolchildren. Orenstein WA; Herrmann K; Albrecht P; Bernier R; Holmgreen P; Bart KJ; Hinman AR Dev Biol Stand; 1986; 65():75-83. PubMed ID: 3556779 [TBL] [Abstract][Full Text] [Related]
48. Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. Halperin SA; McGrath P; Smith B; Houston T J Pediatr; 2000 Jun; 136(6):789-94. PubMed ID: 10839878 [TBL] [Abstract][Full Text] [Related]
49. Prevalence of antibodies against measles, mumps and rubella in Israeli young adults. Danon YL; Adir Y; Abend I; Zaaide Y; Green MS Isr J Med Sci; 1992 Oct; 28(10):733-6. PubMed ID: 1399506 [No Abstract] [Full Text] [Related]
50. Determination of measles, mumps, and rubella immunization status using oral fluid samples. Thieme T; Piacentini S; Davidson S; Steingart K JAMA; 1994 Jul; 272(3):219-21. PubMed ID: 8022041 [TBL] [Abstract][Full Text] [Related]
51. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old]. Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251 [TBL] [Abstract][Full Text] [Related]
52. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia. Feldman S; Andrew M; Norris M; McIntyre B; Iyer R Clin Infect Dis; 1998 Aug; 27(2):388-90. PubMed ID: 9709893 [TBL] [Abstract][Full Text] [Related]
53. [Immune response to various antiviral vaccines]. Tabin R; Berclaz JP; Dupuis G; Peter O Rev Med Suisse Romande; 1993 Dec; 113(12):981-4. PubMed ID: 8290849 [No Abstract] [Full Text] [Related]
54. [Changes in measles, mumps and rubella (MMR) immunity until the year of 2002 after the introduction of MMR vaccination]. Rønne T; Trier H Ugeskr Laeger; 1992 Jul; 154(29):2014-8. PubMed ID: 1509567 [TBL] [Abstract][Full Text] [Related]
55. Combined administration of measles, mumps, rubella, and trivalent oral poliovirus vaccines. Krugman RD; Witte JJ; Parkman PD; Herrmann KL; Meyer HM; Wende RD; Meyer BC; Dungca R Public Health Rep; 1977; 92(3):220-2. PubMed ID: 866558 [No Abstract] [Full Text] [Related]
56. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. Vesikari T; Ohrling A; Baer M; Delem A; Bogaerts H; André FE Acta Paediatr Scand; 1991 Nov; 80(11):1051-7. PubMed ID: 1661057 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859 [TBL] [Abstract][Full Text] [Related]
58. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Miller E; Hill A; Morgan-Capner P; Forsey T; Rush M Vaccine; 1995 Jun; 13(9):799-802. PubMed ID: 7483800 [TBL] [Abstract][Full Text] [Related]
59. Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Ehrenkranz NJ; Ventura AK; Medler EM; Jackson JE; Kenny MT Bull World Health Organ; 1975; 52(1):81-5. PubMed ID: 764997 [TBL] [Abstract][Full Text] [Related]
60. Response to measles revaccination among toddlers in Saudi Arabia by the use of two different trivalent measles-mumps-rubella vaccines. Khalil M; Poltera AA; al-Howasi M; Herzog C; Gerike E; Wegmüller B; Glück R Trans R Soc Trop Med Hyg; 1999; 93(2):214-9. PubMed ID: 10450452 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]